![]() |
市場調查報告書
商品編碼
2109018
心律調節器/去心房顫動導線拔除套件:市場洞察、競爭格局和市場預測 - 2034 年Pacemaker/Defibrillator Lead Extraction Kit - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
心律調節器/去心房顫動導線拔除器套件是一套專用的經皮器械,由電生理學家和經皮外科醫生用於拔除植入時間過長的心律調節器、植入式心臟整流去顫器(ICD) 和心臟再同步治療 (CRT) 導線,這些導線可能已發生感染、功能異常或臨床上不再需要。植入時間過長的導線通常被緻密的纖維組織包裹,並與血管和心臟結構粘連,因此簡單的手動牽引不足以將其拔出。醫生使用鎖定式導絲、可伸縮鞘套以及機械或動力(雷射或射頻)能量來分離黏連組織,釋放導線,並安全地將其拔除。市場依產品類型(整套系統)細分,包括機械拔除系統和動力拔除系統,以及鎖定式導線、鞘套和反向牽引裝置等配件。市場也依最終用戶細分,分為醫院和專科心臟診所。由於 CIED 植入數量不斷增加、器械相關感染疾病發生率不斷上升、專家共識指南建議儘早徹底移除硬體以及能量輔助拔除工具的不斷創新,心律調節器/去心房顫動導線拔除套件已成為經靜脈導線管理過程中必不可少的工具。
心律調節器/去心房顫動導線拔除套件市場的主要成長要素
推動心律調節器/去心房顫動導線拔除套件市場成長的因素
市場促進因素
植入式心臟電子設備的全球負擔日益加重
心律調節器/去心房顫動導線拔除工具包市場最根本的促進因素是全球心律調節器、ICD 和 CRT 植入量的持續成長。新植入的導線在植入數年後最終需要更換、升級或拔除,因此植入數量的累積直接導致需要拔除導線的患者數量增加。隨著設備壽命的延長和患者體內植入多根導線的時間延長,被忽視、損壞或功能過時的硬體的普遍性也在同步上升。電生理科室擴大遇到體內長期植入兩根或更多導線的患者,這些患者需要進行心臟再同步治療或將設備升級為無導線心律調節器系統。無論哪種情況,都可能需要先拔除現有硬體。不斷成長的植入導線數量支撐著對專用拔除工具包在預測期內的強勁且長期的需求。
CIED相關感染疾病發生率增加
器械相關感染疾病是導線拔除中最重要的臨床因素,共識指引將徹底移除植入裝置列為I級推薦,前提是已確診感染疾病。人群數據顯示,約1.1%的植入式心臟電子裝置(CIED)患者在長期追蹤期間發生器械感染疾病,且每次重新置換發生器或導線後,感染疾病風險都會顯著增加。根據ELECTRa(一項納入來自19個歐洲國家73個中心的3500多名患者的大規模多國註冊研究),感染仍然是經靜脈導線拔除的主要適應症之一,其他主要適應症還包括導線功能障礙和非感染性升級需求。隨著全球植入器械總數的增加以及更多患者接受重複手術,預計到2034年,器械感染的累積負擔和相應的拔除次數將持續增加。
市場限制因素
儘管基礎穩固,但心律調節器/去心房顫動導線拔除工具包市場仍面臨諸多限制因素。導線拔除本身就是一項高風險手術,可能導致罕見但致命的併發症,例如上腔靜脈撕裂和心包填塞,因此醫院必須具備快速手術反應和多學科團隊。這使得手術主要集中在大型、資源充足的醫療機構,限制了其更廣泛的應用。電動雷射拔除系統需要大量的初始資本投入、定期校準和維護契約,這對於小規模醫院和專科診所而言可能構成障礙,尤其是在對成本高度敏感的新興市場。經靜脈導線拔除專業訓練醫師的長期短缺限制了手術數量的成長,即使有臨床需求,也難以進行此類手術。研究表明,大多數進行導線拔除術的醫院年手術量較低,這與較低的治療效果有關。導線拔除手術和專用工具包的保險報銷在不同地區仍有差異,而新型能量型拔除技術的嚴格法規核准要求可能會延長其上市時間。儘管 CIED 植入率、感染負擔和指南驅動的需求等潛在因素持續強勁成長,但資金、培訓、安全和保險報銷方面的障礙加在一起,正在減緩部署速度。
Pacemaker/Defibrillator Lead Extraction Kit Market Summary
A pacemaker/defibrillator lead extraction kit is a specialized set of percutaneous tools used by electrophysiologists and cardiac surgeons to remove chronically implanted pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) leads that have become infected, fractured, malfunctioning, or clinically unnecessary. Because chronically implanted leads become encased in dense fibrous tissue and adherent to vascular and cardiac structures, simple manual traction is frequently insufficient, and physicians rely on locking stylets, telescoping sheaths, and either mechanical or powered (laser or radiofrequency) energy to dissect binding sites and free the lead for safe removal. The market is organized by product type across systems, comprising mechanical extraction systems and powered extraction systems, and accessories such as locking stylets, sheaths, and counter-traction devices; and by end-user across hospitals and specialty cardiac clinics. Driven by rising CIED implantation volumes, growing device-related infection rates, expert-consensus guidance favoring early and complete hardware removal, and continued innovation in energy-assisted extraction tools, pacemaker/defibrillator lead extraction kits have become an essential capability within the transvenous lead management pathway.
Pacemaker/Defibrillator Lead Extraction Kit Market Key Growth Drivers
Key Companies in Pacemaker/Defibrillator Lead Extraction Kit Market
The competitive landscape is led by the following active manufacturers:
Factors Contributing to the Growth of the Pacemaker/Defibrillator Lead Extraction Kit Market
Market Drivers
Rising Global Burden of Cardiac Implantable Electronic Devices
The most fundamental driver of the Pacemaker/Defibrillator Lead Extraction Kit market is the steady worldwide growth in pacemaker, ICD, and CRT implantation. Every newly implanted lead becomes, over its multi-year dwell time, a candidate for eventual revision, upgrade, or extraction, so cumulative implant volume directly expands the addressable extraction population. As device longevity extends and patients live longer with multiple leads, the prevalence of abandoned, fractured, or functionally obsolete hardware rises in parallel. Electrophysiology programs are increasingly encountering patients with two or more chronically implanted leads requiring a device upgrade to cardiac resynchronization therapy or a leadless pacing system, each of which may first require extraction of existing hardware. This growing base of implanted leads anchors durable, multi-year demand for dedicated extraction tool kits across the forecast period.
Increasing Incidence of CIED-Related Infections
Device-related infection is the single most important clinical driver of lead extraction, and consensus guidelines classify complete hardware removal as a Class I recommendation whenever infection is confirmed. Population-level data indicate that roughly 1.1% of CIED recipients develop a device infection over long-term follow-up, and infection risk rises substantially with each subsequent generator change or lead revision. The large multinational ELECTRa registry, which enrolled over 3,500 patients across 73 centers in 19 European countries, documented that infection remains a leading indication for transvenous lead extraction, alongside lead malfunction and non-infectious upgrade needs. As the global inventory of implanted devices grows and more patients undergo repeat procedures, the cumulative burden of device infection and the corresponding extraction volume is expected to increase steadily through 2034.
Market Restraints
Despite strong underlying momentum, the Pacemaker/Defibrillator Lead Extraction Kit market faces material constraints. Lead extraction remains an inherently high-risk procedure, with rare but potentially fatal complications such as superior vena cava tears and cardiac tamponade, so hospitals must maintain immediate surgical backup and a multidisciplinary team, which concentrates procedures among larger, well-resourced centers and limits broader adoption. Powered laser extraction systems require significant upfront capital investment, periodic calibration, and service contracts that can be prohibitive for smaller hospitals and specialty clinics, particularly in cost-sensitive and emerging markets. A persistent shortage of physicians formally trained in transvenous lead extraction constrains procedural volumes even where clinical need exists, and studies show that a majority of hospitals performing extraction do so at low annual volumes, which is associated with inferior outcomes. Reimbursement for lead extraction procedures and dedicated tool kits remains uneven across geographies, and stringent regulatory clearance requirements for novel energy-based extraction technologies can lengthen time to market. Together, these capital, training, safety, and reimbursement barriers temper the pace of adoption, even as the underlying drivers of rising CIED implantation, infection burden, and guideline-driven demand remain firmly intact.
Pacemaker/Defibrillator Lead Extraction Kit Market Segment Analysis
The pacemaker/defibrillator lead extraction kit market by product type (system [mechanical extraction system, powered extraction system] and accessories), end-user (hospitals and specialty cardiac clinics), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Product Type
Dominant Subsegment: Mechanical Extraction System.
The mechanical extraction system segment accounted for 46% of the Pacemaker/Defibrillator Lead Extraction Kit market in 2025. Mechanical extraction systems, such as flexible rotating dilator sheath sets, are the leading product type because they require no capital equipment, electricity, or annual maintenance contracts, giving hospitals of nearly any size an economical entry point into percutaneous lead extraction. Their hand- or motor-driven rotational mechanism allows the operator to feel progress through fibrous binding sites, and a single sheath set can extract multiple leads of the same diameter from one patient, reducing per-procedure device cost. Published multicenter experience with contemporary bidirectional mechanical sheaths reports complete lead removal rates around 97% and clinical success rates approaching 99%, reinforcing physician confidence. Systems as a category, encompassing both mechanical and powered extraction platforms, comprise the substantial majority of category revenue, while accessories such as locking stylets, counter-traction devices, and compression coils support nearly every procedure regardless of the primary extraction tool selected. While powered extraction systems are the fastest-growing product type, propelled by their efficiency in dense, long-dwell-time fibrosis, the affordability, simplicity, and broad installed base of mechanical systems secure the segment's leadership across the forecast period.
By End-Users
Dominant Subsegment: Hospitals.
The hospitals segment accounted for 85% of the Pacemaker/Defibrillator Lead Extraction Kit market in 2025. Hospitals are the leading end-user because lead extraction is classified as a high-risk procedure that requires immediate access to cardiac surgical backup, a hybrid operating room or catheterization laboratory equipped for emergency sternotomy, and a multidisciplinary team spanning electrophysiology, cardiac surgery, and anesthesiology. Consensus guidelines explicitly recommend that extraction be performed only at centers capable of managing major vascular or cardiac complications, which concentrates procedure volumes, and therefore kit purchasing, among hospitals rather than outpatient or ambulatory settings. Large academic and tertiary hospitals with high annual extraction volumes are also associated with superior outcomes and lower mortality, encouraging further procedural consolidation within the hospital setting. Specialty cardiac clinics are the fastest-growing end-user as select high-volume, well-resourced cardiac centers build dedicated lead management programs with on-site surgical support, but the safety requirements and infrastructure intensity of the procedure keep hospitals the dominant end-user across the forecast period.
Pacemaker/Defibrillator Lead Extraction Kit Market Region Analysis
Dominant Region: North America
North America accounted for 44% of the global Pacemaker/Defibrillator Lead Extraction Kit market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high per-capita rate of pacemaker and ICD implantation, a mature network of high-volume electrophysiology centers, well-established reimbursement pathways, and the concentrated presence of leading extraction device manufacturers. The United States hosts a dense base of hospitals with dedicated lead management programs and cardiac surgical backup, supporting broad adoption of both mechanical and powered extraction systems. Rising CIED-related infection rates, an aging population with a growing burden of arrhythmia and heart failure, and continued clinical education aligned with updated HRS and multi-society consensus guidance are sustaining strong procedural and device demand. Strong reimbursement, regulatory clarity from the FDA, and proximity to leading device manufacturers anchor the region's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Pacemaker/Defibrillator Lead Extraction Kit market. The region's elevated CAGR is driven by rapidly rising CIED implantation volumes, expanding electrophysiology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China is expanding its base of tertiary cardiac centers capable of performing complex extraction procedures, Japan's aging population is sustaining high rates of device implantation and eventual lead revision, and India is emerging as a lower-cost manufacturing and clinical-training hub for percutaneous cardiac procedures. Rising awareness of device-related infection management, growing government healthcare investment, and the gradual build-out of hybrid operating rooms with surgical backup are accelerating adoption of dedicated extraction kits across the region's higher-volume hospitals. The combination of rising disease burden, expanding device implantation, and improving procedural infrastructure positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global Pacemaker/Defibrillator Lead Extraction Kit market revenue in 2025. The United States dominates on the strength of its high CIED implantation base, dense network of high-volume extraction centers, FDA regulatory clarity, and the concentrated presence of leading mechanical and powered extraction device manufacturers, while growing device infection rates and system-upgrade volumes reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by an established multinational extraction registry infrastructure exemplified by the ELECTRa study, harmonized regulatory pathways under the EU Medical Device Regulation, and a well-developed base of high-volume electrophysiology centers across Germany, France, the United Kingdom, Italy, and Spain. Continued adoption of both laser and mechanical extraction platforms, alongside growing clinical publication activity on extraction outcomes, reinforces the region's role in supplying both diagnostic and therapeutic lead management programs.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising CIED implantation, expanding tertiary cardiac care infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's tertiary cardiac center build-out, Japan's aging-population-driven device volumes, and India's expanding low-cost manufacturing and clinical-training base are accelerating regional adoption of dedicated lead extraction kits.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac care infrastructure, rising CIED implantation rates, and efforts to build dedicated electrophysiology and surgical-backup capability are gradually broadening access to safe percutaneous lead extraction, while training partnerships with established international centers support the build-out of regional procedural capacity.
Pacemaker/Defibrillator Lead Extraction Kit Market Competitive Landscape
The Pacemaker/Defibrillator Lead Extraction Kit market is classified as Moderately Concentrated. Established players with broad, clinically validated product portfolios, including Koninklijke Philips N.V. and Cook Medical, anchor the top tier through decades of clinical evidence and global distribution reach, while specialized and fast-scaling providers such as INVAMED compete through differentiated mechanical and laser platforms, and clinical-stage innovators such as Xtrac O.S. pursue novel, non-thermal extraction technologies, increasing competitive intensity in the powered and next-generation segments.
The competitive landscape can be evaluated across the following dimensions:
Pacemaker/Defibrillator Lead Extraction Kit Market Recent Developmental Activities
In 2026, Koninklijke Philips N.V. continued to expand its Image-Guided Therapy lead management portfolio, reinforcing adoption of its GlideLight laser sheath, which offers adjustable pulse repetition rate to improve advancement efficiency through dense binding sites, and its TightRail and TightRail Sub-C flexible mechanical rotating dilator sheaths designed for tortuous and subclavian vasculature. Strategic significance: Strengthens Philips' position as an integrated provider of both powered and mechanical extraction platforms.
In 2026, Cook Medical continued to broaden its Lead Management portfolio around the Evolution RL and Evolution Shortie RL controlled-rotation dilator sheath sets, alongside the SteadySheath Evolution tissue stabilization sheath and OneTie compression coil used to manage tenacious fibrosis-anchored leads. Strategic significance: Reinforces Cook's long-standing leadership in mechanical, capital-equipment-free lead extraction technology.
Pacemaker/Defibrillator Lead Extraction Kit Market Segmentation
Pacemaker/Defibrillator Lead Extraction Kit Market by Product Type
Pacemaker/Defibrillator Lead Extraction Kit Market by End-Users
Pacemaker/Defibrillator Lead Extraction Kit Market by Geography
Key Takeaways from the Pacemaker/Defibrillator Lead Extraction Kit Market Report Study
Target audience who can benefit from this pacemaker/defibrillator lead extraction kit market report study
Q1. What is the growth rate of the pacemaker/defibrillator lead extraction kit market?
The pacemaker/defibrillator lead extraction kit market is projected to expand at a CAGR of 7.2% during the forecast period from 2026-2034.
Q2. What is the market size of the pacemaker/defibrillator lead extraction kit market?
The pacemaker/defibrillator lead extraction kit market is estimated at USD 1.03 billion in 2025 and is projected to reach USD 1.92 billion by 2034.
Q3. Which region dominates the pacemaker/defibrillator lead extraction kit market?
North America dominated the Pacemaker/Defibrillator Lead Extraction Kit market with a 44% share of global revenue in 2025, supported by a mature immunology treatment ecosystem, deep clinical-research infrastructure, broad payer coverage of biologics, FDA regulatory clarity, and the largest concentration of leading immunology manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the pacemaker/defibrillator lead extraction kit market?
The principal drivers are the rising global burden of cardiac implantable electronic devices; increasing incidence of CIED-related infections, affecting approximately 1.1% of device recipients; growing preference for minimally invasive percutaneous extraction over surgical approaches; continued technological advancement in mechanical and powered extraction tools; rising lead advisories, recalls, and device upgrades; and strengthening clinical guidelines standardizing extraction practice.
Q5. Who are the major players in the pacemaker/defibrillator lead extraction kit market?
The major players include Koninklijke Philips N.V., Cook Medical, and INVAMED, among other active providers profiled in the Competitive Landscape section, along with clinical-stage innovator Xtrac O.S. (Pipeline). Koninklijke Philips N.V. and Cook Medical lead through long-standing clinical evidence and broad, globally distributed extraction tool portfolios.
For illustrative purposes, only a few limited companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.